The "personalized cancer vaccines" (PCVs) used by the nine patients in the trial were targeted to genes specific to their tumors, explained a team led by Dr. David Braun of the Yale Cancer Center in New Haven, Conn.

A new vaccine for kidney cancer shows excellent preliminary results. All patients on the trial had no evidence of cancer three years after the pioneering treatment.

In a Phase 1 study, nine people with advanced kidney cancer became cancer free after receiving personalized vaccines.

An experimental vaccine for kidney cancer is off to a promising start. In data from a Phase I trial released this week, the vaccine candidate appeared to be safe and produced a clear immune response in all nine patients at high risk for recurrences of their cancer.

In a small clinical trial of nine patients with stage III and IV kidney cancer, a personalized anti-tumor vaccine generated robust immune response, according to findings of a new study led by HMS researchers at Dana-Farber Cancer Institute.

Doctors at Dana-Farber say this personalized vaccine can be given after surgery to remove a tumor and train the body’s immune system to eliminate tumor cells.